Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
Provention Bio, Inc. (Nasdaq: PRVB) announced it will report its second quarter 2022 financial results on August 4, 2022, before the U.S. market opens. A conference call will follow at 8:00 am E.T. to discuss the results and company updates. The company focuses on immune-mediated diseases, with its lead investigational drug, teplizumab, having a filed Biologics License Application (BLA) to delay Stage 3 clinical type 1 diabetes. Provention Bio is also developing additional therapies for autoimmune diseases.
- Biologics License Application for teplizumab filed with the FDA.
- Focus on advancing investigational therapies for immune-mediated diseases.
- None.
RED BANK, N.J., July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a company update.
To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Investor Contact:
Robert Doody, VP, Investor Relations
rdoody@proventionbio.com
484-639-7235
Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921
View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-report-second-quarter-2022-financial-results-on-august-4-2022-301595046.html
SOURCE Provention Bio, Inc.
FAQ
When will Provention Bio report its Q2 2022 financial results?
What is the significance of teplizumab for Provention Bio?
What time is the conference call for Provention Bio's Q2 earnings?
How can I access the Provention Bio conference call?
